Eli Lilly and Company is a medicine company which discovers, develops, manufactures, and markets products in a single business segment called human pharmaceutical products. The Company manufactures and distributes its products through facilities in the United States, including Puerto Rico, and in Europe and Asia. Its Cardiometabolic Health products include Basaglar; Humalog, Humalog Mix 75/25, Humalog U-100, Humalog U-200, Humalog Mix 50/50, insulin lispro, and others; Humulin, and others; Jardiance; Mounjaro; Trulicity; Zepbound, and others. Its oncology products include Cyramza, Erbitux, Tyvyt, Verzenio, Retevmo, Jaypirca, and others. Its immunology products include Ebglyss, Olumiant, Omvoh, and Taltz. Its neuroscience products include Emgality and Kisunla. Its LillyDirect, a direct-to-patient digital health care platform, provides delivery of select Lilly medicines dispensed by third-party pharmacies to patients. The Company’s products are sold in approximately 90 countries.
Back to dashboard
Company Information
About this company
Key people
David A. Ricks
Chairman of the Board, President, Chief Executive Officer
Carole Ho
Executive Vice President and President - Lilly Neuroscience
Juan Ricardo Luciano
Lead Independent Director
Raul Alvarez
Independent Director
Katherine Baicker
Independent Director
Carolyn R. Bertozzi
Independent Director
J. Erik Fyrwald
Independent Director
Lucas E. Montarce
Chief Financial Officer, Executive Vice President
Eric Dozier
Executive Vice President, Chief People Officer
Diogo Rau
Executive Vice President, Chief Information and Digital Officer
Daniel M. Skovronsky
Executive Vice President, Chief Scientific and Product Officer and President - Lilly Research Laboratories
Anat Hakim
Executive Vice President, General Counsel, Secretary
Adrienne Brown
Executive Vice President and President - Lilly Immunology
Kenneth Custer
Executive Vice President and President - Lilly Cardiometabolic Health
Edgardo Hernandez
Executive Vice President, President - Manufacturing Operations
Click to see more
Key facts
- Shares in issue941.36m
- EPICLLY
- ISINUS5324571083
- LocationUnited States
- SectorHealthcare
- IndustryBiotechnology & Drugs
- Market cap$1.11tn
- Employees50,000
- ExchangeNew York Stock Exchange
- IndexS&P 500, TR Equity United States Index
- Website
Data policy - All information should be used for indicative purposes only. You should independently check data before making any investment decision. HL cannot guarantee that the data is accurate or complete, and accepts no responsibility for how it may be used. Overview data is sourced from Refinitiv.